Threading the biosimilar needle
Thursday, February 11, 2016 @ 7:00 PM | By Nikolas Purcell and Geoffrey Mowatt
Biosimilars, otherwise known as subsequent entry biologics or “SEBs” in Canada, are a rapidly emerging trend in health care.
Biosimilars present novel and intriguing legal issues that are quickly rising to the forefront of legal commentary.
The complex technology used in the production of biologics is becoming less costly and early patents on the technology are now expiring. Biologics have also been accepted as a crucial treatment option for many indications that should occupy a standard care role, but the cost is often prohibitive.
Biosimilars provide...
Biosimilars present novel and intriguing legal issues that are quickly rising to the forefront of legal commentary.
The complex technology used in the production of biologics is becoming less costly and early patents on the technology are now expiring. Biologics have also been accepted as a crucial treatment option for many indications that should occupy a standard care role, but the cost is often prohibitive.
Biosimilars provide...
